(MedPage Today) — Most patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements receiving pemigatinib (Pemazyre) experienced complete responses in the phase II FIGHT-203 trial.
Among 45 patients analyzed for efficacy, the overall complete…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/117168
Author :
Publish date : 2025-08-26 21:15:00
Copyright for syndicated content belongs to the linked Source.
